Argenx to Acquire Forte Biosciences for $2.2 Billion to Expand Autoimmune Treatment Pipeline

Argenx announced plans to acquire Forte Biosciences for $2.2 billion, significantly expanding its pipeline of treatments for multiple autoimmune diseases. This strategic acquisition demonstrates the pharmaceutical industry's continued investment in developing new therapies for autoimmune conditions that affect millions of patients worldwide. The deal allows Argenx to integrate Forte's drug candidates and research capabilities, potentially accelerating the development of innovative treatments. For patients with autoimmune disorders, this merger could lead to more therapeutic options and faster access to new medications in the coming years.